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Abstract  
 
Background:  Echocardiography is commonly used to direct the management of 
hypertensive disorders in medical patients, but its application in pregnancy is unclear.  Our 
objective was to define the use of echocardiography in pregnancies complicated by 
gestational hypertension (GH) and preeclampsia (PET). 
Methods and Results:  We performed a systematic review of articles using an electronic 
search of databases from inception to March 2015, prospectively registered with PROSPERO 
(CRD42015015700).  Eligible studies included pregnant women with GH or PET, evaluating 
left-ventricular (LV) structure and function using echocardiography.  The search strategy 
identified 36 studies, including 745 women with GH and 815 women with PET.  The 
populations were heterogeneous with respect to clinical characteristics, parity and risk of 
bias.  Increased vascular resistance and LV mass were the most consistent findings in GH and 
PET.  Differentiating features from normal pregnancy were LV wall thickness ≥1.0cm, 
exaggerated reduction in E/A and lateral e’ <14cm/s.  There was disagreement between 
studies with regard to cardiac output due to the timing of echocardiography, although reduced 
stroke volume was an indicator of adverse prognosis.  Diastolic dysfunction and left 
ventricular remodeling are most marked in severe and early-onset PET, but are also markers 
of PET before clinical manifestation, and are associated with adverse outcomes. 
Conclusion: Echocardiography is a valuable tool to stratify risk and can guide management 
and counseling in the preclinical and clinical phases of GH and PET.  Changes in cardiac 
function and morphology are recognizable at an asymptomatic early stage and correlate with 
disease severity and adverse outcomes. 
  
 2 
Introduction 
Cardiac disease is the leading non-obstetric cause of death in pregnancy and the puerperium.
1
  
In uncomplicated pregnancy there is no significant change in systolic blood pressure.
2, 3
 
Diastolic blood pressure and mean arterial pressure decrease during the first trimester, then 
plateau in the second trimester before rising in the final weeks of pregnancy.
2, 3
 Hypertension 
is seen in 6-8% of pregnancies
4
 and the incidence is increasing as the obstetric population 
becomes older and more obese.
5
  Hypertension causes one third of severe maternal 
morbidity
4
 and is the second most common direct cause of maternal mortality worldwide, 
accounting for approximately 14% of maternal deaths.
6
  Adverse fetal outcomes include 
preterm birth, growth restriction and stillbirth.
4
 
 
The hypertensive disorders specific to pregnancy are gestational hypertension (GH) and 
preeclampsia (PET).  Guidelines and terminology vary across the world.
4, 7-10
   The diagnosis 
and classification of these conditions depend on the gestation at which elevated blood 
pressure is identified (GH and PET are acquired conditions in the second half of pregnancy), 
the presence or absence of multisystem involvement or significant proteinuria (traditionally 
the hallmark of PET
4
), and whether the blood pressure normalizes in the postnatal period.  
The onset of hypertension in GH and PET must be after 20 weeks’ gestation to distinguish 
them from chronic hypertension.  PET can develop in patients with GH and also be 
superimposed on chronic hypertension.  
 
Understanding the structure and function of the heart in pregnancy is vital if we are to 
recognize abnormalities at an early stage and plan appropriate interventions to avoid adverse 
outcomes.  Echocardiography is a safe, non-invasive technique to assess cardiac structure and 
function in pregnancy.
11-14
  Although operator-dependent and requiring training to provide 
 3 
reproducible measurements
11
, the temporal variability of echocardiography is small.
15
 
Modern ultrasound technologies can demonstrate subtle changes in cardiac geometry and 
performance
16-19
, and echocardiography has important potential for longitudinal assessment 
in view of its non-invasive nature.  However, evidence for the role of echocardiography for 
serial measurements in pregnancy is lacking, and despite common use in clinical practice, the 
application of echocardiography to study hypertensive disorders of pregnancy is inconsistent.  
 
Our aim was to systematically review the current literature to assess changes in 
echocardiographic structure and function in women developing GH and PET.  We 
hypothesized that echocardiography would be a useful screening tool to identify: (1) high-
risk women in whom recognizable cardiovascular changes occur before manifesting 
clinically as a hypertensive disorder; and (2) women at increased risk following a diagnosis 
of GH or PET.   
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Methods 
Information sources and search strategy 
Studies using echocardiography in pregnancies complicated by GH or PET were eligible for 
inclusion in our systematic review.  The definitions of GH and PET used by each individual 
study were accepted.  Figure 1 shows a typical algorithm for the classification of 
hypertensive disorders of pregnancy.  Our search included MEDLINE, EMBASE, CINAHL 
and the Cochrane Library from inception to March 2015, as well as relevant reference lists.  
The MEDLINE search strategy is shown in Supplementary Table 1, and was adapted for the 
requirements of the other databases.  There was no restriction on the type of study design or 
publication language.  Full text articles were obtained after screening the title and/or abstract 
of eligible studies by two authors (JSC and FT).  The review process was conducted 
according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses 
(PRISMA) checklist 
20
, and prospectively registered with the PROSPERO database 
(CRD42015015700); 
(http://www.crd.york.ac.uk/PROSPERO/DisplayPDF.php?ID=CRD42015015700). 
 
Figure 1 LEGEND: Diagnosis of hypertensive disorders in pregnancy 
A flow chart for contemporary diagnosis of the hypertensive disorders of pregnancy based on 
international guidelines. 
 
Eligibility criteria and study selection 
The population of interest was pregnant women with GH or PET.  Our inclusion criteria 
required an echocardiogram during pregnancy (before and/or after the diagnosis of GH/PET).  
Pregnant women with normal blood pressure were included as a comparison group.  The 
 5 
exclusion criteria were: (1) studies published only in abstract form; (2) duplicate publications 
or publications using the same dataset (in the latter case only the largest study including the 
same patients would be included, unless different data were presented in each paper); (3) case 
reports, editorials, opinion articles, commentaries and letters; (4) animal studies; (5) studies 
including only multiple pregnancies; (6) studies assessing therapeutic effects; and (7) studies 
of pregnant women with chronic hypertension, unless a group with GH or PET were also 
included. 
 
Data collection, outcomes and quality assessment 
A standardized data extraction form was used.  Outcome measures included any 
echocardiographic assessment of left-ventricular (LV) structure or function (see 
Supplementary Table 2 and Supplementary Figure 1).  The Risk of Bias Assessment Tool 
for Non-Randomized Studies (RoBANS)
21
 was used to critique methodological and reporting 
quality of the included manuscripts, addressing key criteria such as selection bias, exposure 
measurement, blinding, the completeness of outcome data and selectivity of reporting.  Two 
authors (JSC and FT) completed the data quality assessment independently, and any 
disagreements were resolved by consensus.   
 
Data synthesis 
Statistical pooling of data from separate studies was not possible because of marked variation 
in study design and reported outcome measures, thus precluding meta-analysis.  Data were 
therefore synthesized qualitatively. 
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Results 
Study selection and study characteristics 
The search strategy identified 36 studies, including 745 women with GH, 815 women with 
PET and 7189 normotensive pregnant controls (see Figure 2).  The characteristics of 
included studies are shown in Table 1.  All studies had an observational design, with 25 case-
control studies,
22-46
 8 cross-sectional studies 
47-54
 and 3 longitudinal cohort studies.
55-57
  The 
majority of studies (n=20) were of women with PET.
22, 27, 29, 30, 32, 33, 39-42, 44-47, 49-51, 54, 56
  There 
were nine studies assessing GH only 
24, 26, 28, 31, 37, 38, 43, 53, 57
 and seven studies evaluating both 
GH and PET.
23, 25, 31, 34, 48, 52, 55
  All investigators recruited women during antenatal visits to 
hospital.  In three of the studies where women were scanned prior to the onset of 
hypertension, the women had already been identified as a high risk group due to fetal growth 
restriction,
47
 raised uterine artery Doppler 
35
 or PET in a previous pregnancy.
56
  
 
Figure 2 LEGEND: Flow chart of systematic review 
Summary of steps in the identification and selection of studies. 
 
The majority of studies investigated patients with a single echocardiogram during the third 
trimester (n=29).  Of the three longitudinal studies, one included echocardiography in each 
trimester
55
 and the other two covered two trimesters.
56, 57
  Considerable heterogeneity was 
seen between and within the study populations (see Table 2), such that meta-analysis was not 
deemed appropriate.  In six studies, a proportion of the patients were on antihypertensive 
therapy.
33, 39, 43, 48, 56, 57
  In two studies, the PET group included a small number of women 
with chronic hypertension and superimposed PET.
48, 56
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Other obstetric outcomes, for example birthweight and gestation at delivery, were recorded in 
15 of the studies.
29, 32, 34, 39, 40, 45-47, 49, 51-56
  Only three authors analyzed the relationship 
between these pregnancy outcomes and echocardiographic measurements
32, 34, 53
 (see 
Supplementary Table 3).  
 
The risk of bias assessment identified variable study quality (see Supplementary Table 4).  
Due to the nature of the studies, the risk of specific biases (particularly blinding) was 
uncertain due to limited reporting in the individual studies.  
 
Synthesis of results 
Results are summarized below according to hemodynamic parameters and systolic function, 
diastolic function, and cardiac structure.  Table 3 presents an overview of findings for the 
main echocardiographic variables investigated in the third trimester studies.  The details of 
extracted parameters from all studies (including the earlier screening studies) are presented in 
Supplementary Table 5.  Figure 3 highlights the major echocardiographic changes that may 
be seen in hypertensive disorders as compared to normal pregnancy.  Supplementary Figure 
2 provides representative images from echocardiograms of women with and without 
gestational hypertensive disease. 
 
Figure 3 LEGEND:  Summary of results 
Summary of major findings comparing normotensive pregnancy with gestational 
hypertension/preeclampsia and association with adverse outcomes.  * A progressive and 
slight increase in left ventricular wall thickness and mass is seen during normal pregnancy 
that regresses post-partum.
58, 59
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Hemodynamics and systolic function 
Total vascular resistance was significantly higher in GH compared with normotensive 
pregnant controls 
25, 36, 37, 43, 55
 but lower than in PET.
31, 55
  In GH, there were conflicting 
reports for cardiac output, including an increase
23, 48, 55, 57
 or no change compared to normal 
pregnancy.
25, 36, 37
  Myocardial performance index and left ventricle (LV) function were 
unchanged in a longitudinal study of GH with second and third trimester measurements.
57
  In 
GH studies with a third trimester echocardiogram, only one showed a significant reduction in 
LV ejection fraction 
37
, whilst three others showed no difference.
24, 37, 57
   
 
In PET, studies covering early trimesters demonstrated that the preclinical phase is 
characterized by a hyperdynamic circulation with high cardiac output and low peripheral 
resistance.
48, 49, 51, 55
  In the second trimester, women who go on to develop PET have 
increased total vascular resistance at mid-gestation, with lower cardiac output.
51, 54
  Once 
PET manifests clinically, there is reduced cardiac output and increased resistance,
50, 55
 
described as a “hemodynamic crossover” in the clinical phase of PET.55  The increased total 
vascular resistance seen in PET
23, 27, 31, 40, 47, 50
 is an independent predictor of adverse maternal 
and fetal outcomes.
53
  In the clinical phase, early onset PET (<34 weeks gestation) is 
characterized by significantly lower cardiac output and higher total vascular resistance 
compared with late onset PET.
51, 54
  Pregnant women who develop recurrent PET have also 
been shown to have lower cardiac output and higher peripheral resistance than women 
without recurrent disease.
56
 
 
Stroke volume is lower in PET than in normal pregnancy 
31, 32
 and in the first trimester this is 
an independent predictor of subsequent development of PET.
49
  Due to the factors discussed, 
cardiac output in PET has been shown to be both lower 
23, 27, 32, 39, 47, 50
 and higher 
27, 31, 40, 48, 49
 
 9 
compared to normotensive pregnancies.  The variation in cardiac output is shown in 
Supplementary Table 5, which also indicates its derivation, since the use of different 
calculations (based either on Doppler or volume calculation) is likely to contribute to the 
disparity for this parameter.  There was similar variability with regard to LV ejection 
fraction, with the majority of studies showing no significant difference compared with 
normotensive pregnant women
27, 41, 45, 46, 50
 and only one showing a decrease.
22
  Myocardial 
performance index was reduced in a study of women with PET and fetal growth restriction in 
the third trimester.
47
  Systolic dysfunction, with marked LV hypertrophy, is significantly 
more common in preterm PET compared to term PET 
35
, even before the condition manifests 
clinically.
51
  
 
Diastolic function 
Several studies have shown that in normal pregnancy the E/A ratio decreases towards term.
3, 
17, 58, 60, 61
  A greater reduction in E/A has been shown in GH compared to pregnancy 
unaffected by hypertension.
24, 36, 37, 44, 57
  
 
Diastolic function is also impaired in PET,
29, 35, 42
 where the usual reduction in E/A is 
exaggerated.
22, 29, 35, 44
  The ratio of early diastolic mitral inflow velocity to early diastolic 
mitral annular velocity (E/e’), was significantly higher in women with PET in five studies, 
suggesting higher LV filling pressures.
27, 29, 42, 46, 51
  Interestingly E/e’ was shown to be 
significantly higher in an early-onset PET subgroup compared with a late-onset subgroup.
29
 
One study used a composite of diastolic indices to diagnose diastolic dysfunction and 
demonstrated diastolic dysfunction in 40% of pregnancies complicated by PET at term, 
compared with 14% of controls.
34
   In another study, diastolic dysfunction was already 
present at 20-23 weeks in women who developed preterm PET, but not PET at term.
51
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Diastolic dysfunction in PET is more marked in cases associated with fetal growth 
restriction
47
, despite evidence that left atrial mechanical function is similar in PET and 
normotensive pregnant controls.
30
 
 
Cardiac structure and remodeling 
In most studies, LV mass was significantly increased in GH compared to normotensive 
pregnant controls in the second 
37
 and third trimester 
24, 26, 28, 36, 37, 43
, and increased in the 
second half of pregnancy when measured serially.
57
  One study identified ventricular 
remodeling or hypertrophy in 91% of patients with GH .
36
  The concentric hypertrophy seen 
in GH
24, 26
 is an independent predictor of adverse pregnancy outcomes.
53
  Other investigators 
found no change in LV mass in GH, showing this instead to be a feature of chronic 
hypertension.
38, 41
  LV/left atrial diameters were increased in GH compared to normotensive 
controls.
27, 44
 
 
LV remodeling is more common in PET compared to normotensive pregnant women in the 
third trimester,
45
 with numerous studies confirming increased LV mass in PET.
22, 24, 27, 29, 30, 34, 
39
  Hypertrophy in PET tends to be of the concentric type
39
, and has been shown in preterm
22, 
29, 35
 and term PET.
30, 34, 35, 44
  In one study, concentric LV remodeling was demonstrated at 
20-23 weeks gestation in 33% of women who subsequently developed PET.
51
  In women who 
progressed to PET from GH, 27% had abnormal LV structure and function at the time of 
echocardiography.
24
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Comment 
We performed a systematic review of all literature pertaining to the use of echocardiography 
in pregnant women with a hypertensive disorder.  Our major findings were increased 
peripheral resistance in GH and PET, diastolic dysfunction in PET and conflicting evidence 
regarding changes in cardiac output.  The echocardiographic changes in cardiac structure and 
function can be detected before the condition is clinically apparent.  Current evidence 
suggests that alterations in PET are not due to hypertension alone, but rather reflect PET as a 
multisystem disorder.  PET has a greater impact on the heart than GH, and changes are most 
pronounced in early onset, severe disease.  
 
Currently, echocardiography is not widely used in the clinical management of hypertensive 
disorders in pregnancy, or as a screening tool for PET.  The application of echocardiography 
in pregnancy has traditionally been in patients with adult congenital cardiac disease, in acute 
illness or for research purposes.  The management of hypertensive disorders in pregnancy is 
based on maternal clinical assessment (symptoms, blood pressure and laboratory parameters) 
and fetal wellbeing.  A decision to deliver the baby can be for maternal or fetal reasons. 
Whereas other reviews have focused on congenital heart disease
62
 or described 
echocardiographic changes in the context of a broad overview of the management of PET
63
, 
ours is the first systematic review of cardiac structure and function in gestational 
hypertensive disease. 
 
Clinicians now recognize that PET should no longer be considered as a single disease 
process.  There is evidence to suggest that preterm hypertension and proteinuria associated 
with fetal growth restriction is different to hypertension and proteinuria at term when 
birthweights tend to be normal or increased.
64
  The possible difference in the mechanism of 
 12 
disease and how it manifests clinically
65
 may be responsible for the conflicting results 
between studies when early- and late-onset PET are considered as one entity.  The 
contradictory hemodynamic models described can be explained by noting the distinction 
between early PET 
51, 54
 and late-onset disease.
53, 55
 
 
Although based on observational data, our review suggests that echocardiography has the 
potential to improve the management of patients with hypertension during pregnancy and 
categorize patients with GH or PET into high and low risk groups.  Patients with increased 
vascular resistance and LV mass are more likely to have complications.
53
  As a predictor of 
long term cardiovascular morbidity, diastolic dysfunction in pregnancy is important to 
identify,
34
 and reduced e’ (and therefore elevated E/e’) may be a useful and early predictor of 
PET.
47
  Echocardiography can also help to identify the small numbers of women with LV 
systolic impairment who are more likely to deteriorate during pregnancy or post-partum.  
With the currently available data, we suggest the most efficient use of echocardiography is 
after the diagnosis of hypertension, to direct resources to the most vulnerable patients in order 
to improve maternal (and fetal) outcomes (see Figure 4).  The optimal timing of 
echocardiography needs further study.  Whereas an early echocardiogram in the first and 
second trimesters may be helpful for risk stratification, the available data on clinical impact is 
currently limited. 
 
Figure 4 LEGEND:  Potential value of echocardiography in hypertensive disorders of 
pregnancy 
BP, blood pressure; GH, gestational hypertension; PET, preeclampsia.  * Diastolic 
dysfunction can be further graded into impaired myocardial relaxation (E/A <0.73, 
deceleration time [DT] >194ms, isovolumetric relaxation time [IVRT] >83ms), 
pseudonormal filling (E/A 0.73-2.33, DT 138-194ms, IVRT 51-83ms) and restrictive filling 
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(E/A >2.33, DT <138ms, IVRT <51ms).  Left atrial dilatation is also a useful 
echocardiographic marker.  For further details, see Melchiorre et al., 2011 
34
, adapted from 
recommendations by Nagueh et al.
66
  GH/PET risk assessment based on UK National 
Institute for Health and Clinical Excellence guidelines.
4
 
 
It has also been suggested that echocardiography can stratify hypertensive pregnant women 
into hemodynamic subgroups, thereby enabling clinicians to tailor their choice of 
antihypertensive therapy.
49
  Hypertension characterized by vasoconstriction responds better 
to beta-blockade whereas in hypertension with reduced plasma volume, calcium channel 
blockers are preferable, as they reduce afterload and improve cardiac function.
67
 
Echocardiography can also have an important role in guiding fluid balance, one of the most 
challenging aspects in the management of PET.  Overzealous fluid administration can lead to 
pulmonary edema, and conversely if a patient is under-filled, end-organ dysfunction may 
worsen.  In selected centers and patients, myocardial strain imaging has been shown to be 
more sensitive than LV ejection fraction in detecting differences in LV systolic function in 
women with and without PET.
36
   Strain measurements can potentially provide more 
information about cardiac function but due to limited data
33, 34, 39, 52
, further investigation is 
required. 
 
In summary, echocardiography can reveal cardiac impairment in GH and PET, which 
changes antenatal management (medication, frequency of monitoring, timing of delivery) and 
can indicate when postnatal follow-up is warranted.  More longitudinal studies are required to 
evaluate the cardiovascular changes in hypertensive disorders throughout pregnancy and to 
further define the role of echocardiography in the antenatal assessment of women with GH 
and PET, and in subsequent pregnancies.  It would be useful in clinical and research practice 
to define an ideal dataset for echocardiographic assessment in pregnancy, and agreed 
 14 
outcome measures for studies of cardiac structure and function, so that results are comparable 
and pooled data can be analyzed quantitatively.  Clinicians should follow the American and 
European consensus guidelines
68
 with specific focus on the variables listed in Figure 4.  
Developing collaboration between Cardiologists and Obstetricians has the potential to open 
up new areas of research and further improve patient care. 
 
Limitations 
The main limitation of our assessment was the wide variation in patient groups (age, 
ethnicity, body habitus, parity, timing of assessment, disease severity) and reported outcome 
measures.  In several studies the participants were grouped based on outcomes other than 
hypertensive disorder diagnosis.  This heterogeneity restricts quantitative synthesis of results 
and meta-analysis.  Many of the included studies involve small numbers of patients, with 
varying levels of risk for important bias and likely different levels of echocardiographer 
experience.  A substantial amount of data is derived from load-dependent indices, which may 
be inferior to measurements that take into account the different loading conditions seen in 
pregnancy.  The cross sectional studies capture women at different stages of the disease and 
offer only a snapshot at a single point in time.  At present, there is a paucity of longitudinal 
data in pregnancy.  Only one of the longitudinal studies considered the reproducibility of the 
echocardiographic measurements, and whilst these results were encouraging (intraobserver 
variability 2.4% for cardiac output and 2.0 % for total vascular resistance
55
), further data in 
pregnant patients are clearly needed. 
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Conclusion 
This systematic review demonstrates that cardiac structure and function using 
echocardiography are altered in the preclinical and clinical phases of gestational hypertension 
and preeclampsia.  For women with preeclampsia, diastolic dysfunction and increased 
peripheral vascular resistance correlate with disease severity.  Recognition of impairment in 
cardiac function is important in the contemporary management of gestational hypertension 
and preeclampsia, in order to improve pregnancy outcomes and long-term cardiovascular 
health. 
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Table 1: Characteristics of included studies 
T
r
im
es
te
r 
Author, year 
Population 
(Country) 
Inclusion 
criteria  
Exclusion criteria Controls/comparison 
Timing of 
echocardiography 
(gestational age in 
weeks) 
Longitudinal cohort studies 
1 
-3 
Bosio, 1999 
55
 Antenatal patients 
attending hospital 
(Ireland) 
GH or PET Parity >0; cardiac disease; essential hypertension; chronic illness; 
long term medication; multiple pregnancy; significant obstetric or 
medical complication 
Nil 5 appointments: 10-
14; 20-24; 28-32; 
34-36; 37-40 
1 
-2 
Sep, 2011
56
 Women with PET 
in previous 
pregnancy 
(Netherlands) 
Previous 
early onset 
PET 
Multiple pregnancy; renal disease; missed > 2 appointments Nil Prior to pregnancy 
and 12, 16, 20 
weeks 
2 
-3 
Vlahovic-Stipac, 
2010 
57
 
Antenatal patients 
attending hospital 
(Serbia) 
GH Essential hypertension; diabetes; structural heart disease Normotensive pregnant 24±3 and 36±1 
Cross sectional studies 
1 De Paco, 2008 
48
 Antenatal patients 
attending hospital 
(UK) 
Live 
singleton 
pregnancy 
Multiple pregnancy; missing outcome data; miscarriage; termination 
of pregnancy; major anomalies at birth 
Normotensive pregnant 
women split into two groups: 
SGA (n=532) and 
uncomplicated (n=3591) 
11+0 to 13+6  
Khaw, 2008 
49
 Antenatal patients 
attending hospital 
(UK) 
PET Parity >0; medications; unavailable outcomes; fetal loss; maternal 
disease 
Nil 11-14 
2 Melchiorre, 
2013
51
 
Uterine artery 
Doppler 
pulsatility index > 
95th centile 
(UK) 
Uterine 
artery 
pulsatility 
index 
>95th 
centile 
Parity >0; essential hypertension; proteinuria prior to 20 weeks 
gestation; comorbidities; smoking; medication; fetal anomalies; 
persistent hypertension after 12 weeks post-partum 
Women with normal uterine 
artery pulsatility index and 
women with raised pulsatility 
index (term delivery) 
20-23 
2 Valensise, 2008 
54
 Normotensive 
pregnant women 
with bilateral 
notching of 
umbilical artery at 
20-22 weeks 
(Italy) 
Bilateral 
umbilical 
artery 
notching  
Multiple pregnancy; undetermined gestational age; smoking; multiple 
pregnancy; cardiac disease; pre-existing medical problem; fetal 
anomalies; persistent hypertension at 1 year follow up 
Normotensive pregnant 24 
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T
r
im
es
te
r 
Author, year 
Population 
(Country) 
Inclusion 
criteria  
Exclusion criteria Controls/comparison 
Timing of 
echocardiography 
(gestational age in 
weeks) 
3 Bamfo, 2008 
47
 Pregnant women 
with fetal growth 
restriction (UK) 
Diagnosis 
of fetal 
growth 
restriction 
GH; multiple pregnancy; co-morbidities; medication; fetal anomalies; 
chromosomal abnormalities; genetic syndromes; infections 
Normotensive with fetal 
growth restriction 
28 (24-35) 
Estensen, 2013 
50
 Antenatal patients 
attending hospital 
(Norway) 
PET Essential hypertension; diabetes; renal impairment; hyperlipidemia; 
uncontrolled endocrine or rheumatological disease; cardiovascular 
disease 
Non-pregnant with previous 
PET 
36 
Shahul, 2012 
52
 Antenatal patients 
attending hospital 
(USA) 
GH or PET Multiple pregnancy; age < 18 years; gestation < 24 weeks pre-
existing cardiovascular disease; pulmonary disease; diabetes; poor 
image quality; preterm prelabor rupture of membranes 
Nil NTP 38 (35.6-
39.6); 
GH 36.4 (33.4-
38.1); 
PET 36.6 (32.7-
37.4)  
Valensise, 2006 
53
 Antenatal patients 
attending hospital 
(Italy) 
Mild GH Systolic blood pressure >150; diastolic blood pressure >100; 
proteinuria; essential hypertension; hemolysis, elevated liver 
enzymes and low platelets (‘HELLP’); antihypertensive therapy; 
small for gestational age fetus; abnormal fetal Doppler; abnormal 
liquor volume; undetermined gestational age; smoking; multiple 
pregnancy; maternal heart disease; maternal chronic medical 
problems; fetal anomaly 
Normotensive pregnant 28-31 
Case control studies 
3 Borghi, 2000 
22
 Antenatal patients 
attending hospital 
(Italy) 
PET Essential hypertension; secondary hypertension; obesity; diabetes; 
cardiomyopathy; valvular heart disease; major electrocardiogram 
abnormality 
Normotensive pregnant and 
non-pregnant 
NTP 30.9±4.0; 
PET 28.4±6.0 
Borghi, 2011 
23
 Antenatal patients 
attending hospital  
(Italy) 
GH or PET Possible double or overlapping diagnosis Chronic hypertension, 
normotensive pregnant 
NTP 30.5±5; 
GH 31.2±4; 
PET 30.0±5 
Cho, 2011
24
 Antenatal patients 
attending hospital 
(South Korea) 
GH Diabetes; essential hypertension; cardiac disease Normotensive pregnant NTP 35.1±3.4; 
GH 33.3±3.6 
Degani, 1989 
25
 Antenatal patients 
attending hospital 
(Israel) 
GH or PET Multiple pregnancy; previous hypertension; previous heart disease; 
antihypertensive therapy 
Normotensive pregnant third trimester 
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T
r
im
es
te
r 
Author, year 
Population 
(Country) 
Inclusion 
criteria  
Exclusion criteria Controls/comparison 
Timing of 
echocardiography 
(gestational age in 
weeks) 
Demir, 2003 
26
 Antenatal patients 
attending hospital 
(Turkey) 
GH Essential hypertension Normotensive pregnant 38 
 Dennis, 2012 
27
 Antenatal patients 
attending hospital 
(Australia) 
PET In labor; smoking; vasoactive medication; critically ill requiring 
urgent antihypertensive or magnesium sulfate 
Normotensive pregnant and 
non-pregnant 
36±4 
Escudero, 1988 
28
 Antenatal patients 
attending hospital 
(Argentina) 
GH Parity >0; age under 16; history of heart disease; multiple pregnancy Non-pregnant 26-42 
Hamad, 2009 
29
 Antenatal patients 
attending hospital 
(Sweden) 
PET Parity >0; smoking; assisted conception; multiple pregnancy; 
clinically unstable; antihypertensive therapy; chronic disease; 
extreme obesity 
Normotensive pregnant NTP 33±4; 
PET 35±4 
Ingec, 2005 
30
 Antenatal patients 
attending hospital 
(Turkey) 
PET Not stated Normotensive pregnant NTP 38±1; 
PET 37±3 
Kuzniar, 1982 
32
 Antenatal patients 
attending hospital 
(Poland) 
PET Multiple pregnancy; uncomplicated pregnancy; cardiorespiratory 
disease 
Normotensive pregnant and 
pregnant with essential 
hypertension 
30-40 
Kuzniar, 1992 
31
 Antenatal patients 
attending hospital 
(Poland) 
Mild GH Previous hypertension; renal disease; persistent hypertension 3 
months post-partum; hypertension prior to 3rd trimester; SBP > 160; 
DBP >110   
Normotensive pregnant 32-41 
Lang, 1991 
33
 Antenatal patients 
attending hospital 
(USA) 
PET Parity >0; regional wall motion abnormalities Normotensive pregnant "early labor" 
"late third 
trimester" 
Melchiorre, 
2011
34
 
Antenatal patients 
attending hospital 
(UK) 
GH or PET Multiple pregnancy; co-morbidities; smoking; antihypertensive 
therapy 
Normotensive pregnant 37 (37.5 - 39)  
Melchiorre, 
2012
35
 
Antenatal patients 
attending hospital 
(UK) 
PET Multiple pregnancy; comorbidity; smoking; medication;  Normotensive pregnant (50 
term; 54 preterm) 
preterm NTP 32 
(28.6 - 35.7); 
preterm PET 35.5 
(28.1-35.8) 
Novelli, 2003 
36
 Antenatal patients 
attending hospital 
(Italy) 
GH Multiple pregnancy; medications other than vitamins/iron; 
indeterminate gestational age; smoking; cardiac disease; 
antihypertensive therapy; pre-existing medical problem 
Normotensive pregnant and 
non-pregnant with essential 
hypertension 
31(3) weeks 
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T
r
im
es
te
r 
Author, year 
Population 
(Country) 
Inclusion 
criteria  
Exclusion criteria Controls/comparison 
Timing of 
echocardiography 
(gestational age in 
weeks) 
 
Oren, 1996 
37
 Antenatal patients 
attending hospital 
(Israel) 
GH Essential hypertension; diabetes; renal disease; molar pregnancy; 
hydrops 
Normotensive pregnant and 
patients with gestational 
diabetes mellitus 
NTP 32±3.3; 
GH 32±2.4 
Sanchez, 1986 
38
 Antenatal patients 
attending hospital 
(Argentina) 
GH Complicated pregnancy; cardiorespiratory disease Normotensive pregnant; non-
pregnant; pregnant with 
essential hypertension 
32 
Simmons, 2002 
39
 Antenatal patients 
attending hospital 
(Australia) 
PET Medical co-morbidities; essential hypertension; diabetes; multiple 
pregnancy; vasoactive medication 
Normotensive pregnant and 
non-pregnant 
NTP 12±2, 22±1, 
35±5; 
PET 35±4 
Solanki, 2011 
40
 Antenatal patients 
attending hospital 
(India) 
PET Multiple pregnancy; unsure of dates; essential hypertension; cardiac 
disease; moderate or severe anemia; multiple pregnancy; alcohol use; 
smoking 
Normotensive pregnant > 34 weeks 
Thompson, 
1986 
41
 
Antenatal patients 
attending hospital 
(USA) 
PET Essential hypertension; medication Normotensive pregnant 32-38 
Tyldum, 2012 
42
 Antenatal patients 
attending hospital 
(Norway) 
PET Diabetes; essential hypertension; cardiac disease; multiple pregnancy Normotensive pregnant 27-40 (mean 35) 
Veille, 1984 
43
 Antenatal patients 
attending hospital 
(USA) 
GH Essential hypertension; antihypertensive therapy other than 
magnesium sulfate or diuretics; multiple pregnancy 
Normotensive pregnant 38±2 
Yuan, 2006 
44
 Antenatal patients 
attending hospital 
(China) 
PET Essential hypertension; renal disease; cardiac disease; diabetes Normotensive pregnant mean 39 
Yuan, 2014 
45
 Antenatal patients 
attending hospital 
(China) 
PET Parity >0; multiple pregnancy; GH; essential hypertension; risk 
factors for arterial stiffening (smoking; obstructive sleep apnea; in 
vitro fertilization; diabetes; hypercholesterolemia) 
Normotensive pregnant 35.6±3.4 
Zieleskiewicz, 
2014 
46
 
Antenatal patients 
attending hospital 
(France) 
PET Age under 18; post-partum PET Normotensive pregnant NTP 37 (36-39); 
PET 34 (31-35) 
Data are presented as means ± standard deviation or medians (interquartile range).   
GH, gestational hypertension; NTP, normotensive pregnant control; PET, preeclampsia. 
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Table 2: Characteristics of patients in included studies 
Author, year 
Number 
of 
women 
Number of cases Age Parity 
NTP GH PET NTP GH PET NTP GH PET 
Bamfo, 2008 
47
 36 19 0 17 26±6 n/a 29±7 38% 
P0; 
21% 
P1; 5% 
P2 
n/a 94% 
PO; 6% 
P2 
Borghi, 2000 
22
 85 35 0 40 31±3 n/a 31±5 2±7 n/a 2±1 
Borghi, 2011 
23
 112 39 24 33 31±4 29±5 32±5 2±1 2±1 2±1 
Bosio, 1999 
55
 378 334 24 20 24 (95% 
CI 24, 
25) 
28 (95% 
CI 26, 
30) 
24 (95% 
CI 23, 
26) 
100% 
P0 
100% 
P0 
100% 
P0 
Cho, 2011 
24
 199 93 106 0 30±4 32±4 n/a not reported 
De Paco, 2008 
48
 4617 4123 87 83 32 
(range 
15-47) 
32 
(range 
17-46) 
32 
(range 
18-49) 
48% P0 56% 
P0 
64% P0 
Degani, 1989 
25
 32 14 18 0* 27±6 25±5 n/a 100% 
P0 
100% 
P0 
n/a 
Demir, 2003 
26
 92 56 36 0 26±6 29±9 n/a not reported 
Dennis, 2012 
27
 100 40 0 40  
(6 early; 
34 late) 
32±4 n/a 31±5 25% P0 n/a 65% P0 
Escudero, 1988 
28
 29 10 9 0 27 
(SD not 
given) 
24  
(SD not 
given) 
n/a 100% 
P0 
100% 
P0 
n/a 
Estensen, 2013 
50
 145 65 0 40 32±5 n/a 32±6 58% P0 n/a 67% P0 
Hamad, 2009 
29
 65 30 0 35 
(8 early;  
27 late)  
31±4 n/a 31±5 100% 
P0 
n/a 100% 
P0 
Ingec, 2005 
30
 37 17 0 20 29±6 n/a 32±7 not reported 
Khaw, 2008 
49
 534 457 0 27 30 (25 -
33) 
n/a without 
SGA 31 
(22 -33);  
with 
SGA 31 
(24 - 35) 
100% 
P0 
n/a 100% 
P0 
Kuzniar, 1982 
32
 47 19 0 19 26 
(range 17 
- 31) 
n/a 27 
(range 15 
- 32) 
100% 
P0 
n/a 100% 
P0 
Kuzniar, 1992 
31
 72 27 22 23 24±4 24±4 22.5±4.1 100% 
P0 
100% 
P0 
100% 
P0 
Lang, 1991 
33
 20 10 0 10 22±5 n/a 20±4    
Melchiorre, 2011 
34
 
120 50 20 50 32 (26-
36) 
n/a 32.0 (29-
37) 
100% 
P0 
n/a 100% 
P0 
Melchiorre, 2012 
35
 
181 104 
(50 term; 
54 
preterm) 
0 77  
(27 
preterm;  
50 term) 
32 (28-
36) 
n/a 30 (27-
35) 
59% P0 n/a 67% P0 
 28 
Author, year 
Number 
of 
women 
Number of cases Age Parity 
NTP GH PET NTP GH PET NTP GH PET 
Melchiorre, 2013 
51
 
214 168 0 46 
(18 
preterm; 
 28 term) 
low risk 
32 (26-
34);  
high risk 
32  
(26-35) 
n/a term 32 
(30-37);  
preterm 
30  
(24-34) 
100% 
P0 
n/a 100% 
P0 
Novelli, 2003 
36
 114 38 36 0 32±6 31±6 n/a not reported 
Oren, 1996  
37
 30 10 10 0 23±2 23±3 n/a not reported 
Sanchez, 1986 
38
 69 22 16 0 23 (range 
21-24) 
26 (range 
16-36) 
n/a 100% 
P0 
100% 
P0 
n/a 
Sep, 2011 
56
 34 24 0 10 33±5 n/a 30±5 100% 
parous 
n/a 100% 
parous 
Shahul, 2012 
52
 39 17 11
†
 11 
(3 
severe;  
8 mild) 
29 (25-
33) 
35.5 (28-
39) 
32 (26-
34)  
0  
(0-0) 
0  
(0-1) 
0  
(0-2) 
Simmons, 2002 
39
 71 44 0 15 29±5 n/a 32±6 not reported 
Solanki, 2011 
40
 40 20 0 20 
(12 mild; 
8 severe) 
25±2 n/a 26±4 not reported 
Thompson, 1986 
41
 
35 11 0 10 24 (range 
19-29) 
n/a 24 (range 
16-34) 
mean 1 
(range 
0-5) 
mean 0 
(range 
0-1) 
n/a 
Tyldum, 2012 
42
 40 20 0 20 27±4 n/a 29±5 65% P0 n/a 65% 
P0 
Valensise, 2006 
53
 
309 41 268 17  
(in comp. 
group) 
32±3 uncomp.
32±4; 
comp. 
33±4 
n/a 27% P0 Uncom
p. 29% 
P0; 
comp. 
44% P0 
n/a 
Valensise, 2008 
54
 
1226 1119 0 107 
(75 early; 
32 late) 
32±5 n/a early 
34±4; 
late 32±4 
100% 
P0 
n/a 100% 
P0 
Veille, 1984 
43
 40 17 23 0* 29±4 25±5 n/a 21% P0 96% P0 n/a 
Vlahovic-Stipac, 
2010 
57
 
47 12 35 0 30±4 30±6 n/a not reported 
Yuan, 2006 
44
 56 24 0 32 27±3.1 n/a 27±3 not reported 
Yuan, 2014 
45
 63 40 0 23 27±3 n/a 29±6 100% 
P0 
n/a 100% 
P0 
Zieleskiewicz, 
2014 
46
 
40 20 0 20 30 (26-
34) 
n/a 31 (26-
38) 
35% P0 n/a 45% P0 
Data are presented as means ± standard deviation or medians (interquartile range). 
 * Definition of GH could include patients with PET; 
†
 GH group includes patients with essential 
hypertension.  
Comp., complicated; uncomp., uncomplicated; GH, gestational hypertension; n/a, not applicable; NTP, 
normotensive pregnant control; P1, parity 1 etc.; PET, preeclampsia; SGA, small for gestational age 
fetus. 
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Table 3: Summary of findings in third trimester studies 
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* third trimester results from longitudinal study; 
†
 all cases early preeclampsia (before 34 weeks gestation); 
‡
 studies with post natal follow up. 
, significant increase; , significant decrease; =, no significant difference compared to controls; CO, cardiac output; G, gestational hypertension; LVEF, 
left ventricular ejection fraction; LVM, left ventricular mass; P, preeclampsia; TVR, total vascular resistance.
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Figure 1:  Diagnosis of hypertensive disorders in pregnancy 
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Figure 2:  Flow chart of systematic review 
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Figure 3:  Summary of results 
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Figure 4:  Potential value of echocardiography in hypertensive disorders of pregnancy 
 
